ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 25, Citizens JMP lifted the price target on the company’s stock to $114 from $95, while keeping an “Outperform” rating, as reported by The Fly. This announcement follows ABIVAX Société Anonyme stating that results from the Obefazimod Phase 3 induction trials would be presented next month. As per the firm, the Phase 3 results can reinforce the strength of Obefazimod’s efficacy and increase conviction in the multi-billion-dollar sales potential.
ABIVAX Société Anonyme’s operating loss rose by EUR 13.7 million to EUR -93.7 million for the 6 months to June 30, 2025, compared to EUR -80.0 million for the same period of the previous year. Operating income, consisting mainly of Research Tax Credit and Subsidies, fell by EUR 4.7 million to EUR 2.1 million for 6 months to June 30, 2025, as compared to EUR 6.8 million for 6 months ending June 30, 2024. The rise in operating loss was due to the operating expenses.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
This article is originally published at Insider Monkey.
